Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: SCOPE OF N SAID-AS SOCIATED GASTROINTESTINAL TOXICITY Part 2


DyspepsiaDyspepsia is common, with an estimated prevalence in Canada of 28.6%. It is unclear whether NSAID therapy causes dyspepsia or simply worsens a pre-existing condition. Studies indicate that 15% to 25% of patients taking NSAIDs experience dyspepsia and that, due to intolerance, treatment is discontinued or medication is changed in about 10% of patients. Clinical trials enroll highly selected patient populations and exclude patients with co-morbidity and extensive use of comedication; therefore, estimates of NSAID-related dyspepsia rates may be biased. A recent telephone survey reported that 48% of patients with arthritis and 30% of patients suffering from hypertension who were taking NSAIDs experienced dyspepsia. These findings are consistent with those of a previous metaanalysis demonstrating a positive association between NSAID use and dyspepsia. Learn how to save money – buy antibiotics online to enjoy your shopping and your treatment.

This entry was posted in Coxibs and tagged Coxibs, Cyclooxygenase-2 inhibitors, Gastroprotective agents, Nonsteroidal anti-inflammatory drugs.